Washington, D.C. – Results of a recent study conducted by researchers at Georgetown University suggest that the use of Pritalin, a version of the ADHD drug Ritalin specially formulated for second- and third-trimester fetuses, can significantly reduce symptoms of in-the-womb hyperactivity in unborn children. "Our research shows that the daily use of Pritalin by an expectant mother can have dramatic results in calming the behavior of an unborn child who is fidgeting and fussing around and whatnot in the womb — a period during which the fetus should instead remain mostly docile as it focuses one hundred percent on its physical development," said Dr. John H. Ryan, lead researcher on the study.
Read the rest in Recoil Magazine
No comments:
Post a Comment